EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RSP1141, a reversible non-covalent BTK inhibitor, suppresses GPVI-mediated platelet activation

Taeryeong Kim, Yeojeong Kim, Jisue Sohn, Jingyang Sun, Yejin Kim, Bomi Park, Minju Kim, Solee Kim, Eun-Bee Oh, Ji Won Park, Dahyun Kang, Jae-Sang Ryu und 1 weitere

Life Sciences · 2026-11 · 124772

DOI: 10.1016/j.lfs.2026.124772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026-11. Verfasst von Taeryeong Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. Electronic address: taeryeong@snu.ac.kr. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Ministry of Education, Korea Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The glycoprotein VI (GPVI)-Bruton's tyrosine kinase (BTK) axis drives collagen-induced platelet activation and arterial thrombosis. Approved BTK inhibitors act irreversibly on Cys481, raising concerns over off-target kinase inhibition, C481S resistance, and bleeding. We aimed to identify a non-covalent, reversible BTK inhibitor with antiplatelet activity and to define quantitatively its selectivity within the platelet GPVI cascade. MATERIALS AND METHODS: Fifty-five imidazo[4,5-b]pyridine derivatives were screened using a BTK enzymatic assay and CRP-XL-induced aggregation of washed human platelets. The lead compound, RSP1141, was characterized by concentration-response immunoblotting of GPVI signaling nodes, Ca2+ mobilization, functional assays, drug washout, 370-kinase profiling, C481S enzymatic assay, molecular docking, and a murine FeCl₃-induced arterial thrombosis and tail-bleeding model. KEY FINDINGS: RSP1141 inhibited BTK (IC₅₀ 27.9 nM) and CRP-XL-induced aggregation (IC₅₀ 173.6 nM). In intact platelets, RSP1141 inhibited BTK-pY223 (IC₅₀ 0.316 μM) and PLCγ2-pY753 (0.325 μM) at essentially identical concentrations, whereas SYK-pY525/526 (2.88 μM) and Src-family kinase-pY416 (3.96 μM) required 9.1- and 12.5-fold higher concentrations. Downstream PKC, Ca2+, granule secretion, integrin, and spreading responses were suppressed. RSP1141 retained activity against C481S BTK (IC₅₀ 141 nM), docking predicted no covalent Cys481 engagement, and platelet aggregation and BTK-PLCγ2 signaling recovered after washout. In mice, oral RSP1141 delayed FeCl₃-induced carotid occlusion at 10 mg/kg, whereas tail bleeding time was not detectably prolonged. SIGNIFICANCE: RSP1141 engages the BTK-PLCγ2 node with approximately 10-fold cellular selectivity over proximal GPVI kinases, inhibits reversibly, and is antithrombotic in vivo without detectable bleeding prolongation, providing a mechanistically differentiated antiplatelet lead.

Schlagwörter

Stichwörter der Autor:innen

Antiplatelet agentArterial thrombosisBruton's tyrosine kinaseGPVI signalingNon-covalent BTK inhibitorPlatelet activation

Autor:innen und Institutionen

  • College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. Electronic address: taeryeong@snu.ac.kr.
  • College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea. Electronic address: yeojeong1564@ewha.ac.kr.
  • College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. Electronic address: jisue05180@snu.ac.kr.
  • College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea. Electronic address: sunjingyangs@163.com.
  • College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea. Electronic address: kyj077533@gmail.com.
  • College of Pharmacy, Ewha Womans University, Seoul, 03760, Republic of Korea. Electronic address: boml010205@gmail.com.

Förderung

  • Korea Ministry of Education
  • Korea Ministry of Science and ICT

Zitieren

APA

Kim, T., Kim, Y., Sohn, J., Sun, J., Kim, Y., Park, B., Kim, M., Kim, S., Oh, E. B., Park, J. W., Kang, D., Ryu, J. S., & Chang, T. S. (2026). RSP1141, a reversible non-covalent BTK inhibitor, suppresses GPVI-mediated platelet activation. Life Sciences, 124772. https://doi.org/10.1016/j.lfs.2026.124772

Vancouver

Kim T, Kim Y, Sohn J, Sun J, Kim Y, Park B, et al. RSP1141, a reversible non-covalent BTK inhibitor, suppresses GPVI-mediated platelet activation. Life Sciences. 2026:124772. doi:10.1016/j.lfs.2026.124772

BibTeX
@article{Kim2026,
  author = {Kim, Taeryeong and Kim, Yeojeong and Sohn, Jisue and Sun, Jingyang and Kim, Yejin and Park, Bomi and Kim, Minju and Kim, Solee and Oh, Eun-Bee and Park, Ji Won and Kang, Dahyun and Ryu, Jae-Sang and Chang, Tong-Shin},
  title = {RSP1141, a reversible non-covalent BTK inhibitor, suppresses GPVI-mediated platelet activation},
  journal = {Life Sciences},
  year = {2026},
  pages = {124772},
  doi = {10.1016/j.lfs.2026.124772}
}
Kostenlos starten →